Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients.

Autor: Ligorio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy; IFOM ETS, the AIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy., Vingiani A; Oncology and Hematology-Oncology Department, University of Milan, Via Festa del Perdono 7, 20122 Milano, Italy; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Torelli T; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Sposetti C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy; Oncology and Hematology-Oncology Department, University of Milan, Via Festa del Perdono 7, 20122 Milano, Italy., Drufuca L; IFOM ETS, the AIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy., Iannelli F; Haematopathogy Division, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy., Zanenga L; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Depretto C; Department of Radiology and Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Folli S; Surgical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Scaperrotta G; Department of Radiology and Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Capri G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Bianchi GV; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Ferraris C; Surgical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Martelli G; Surgical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Maugeri I; Surgical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Provenzano L; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy; Oncology and Hematology-Oncology Department, University of Milan, Via Festa del Perdono 7, 20122 Milano, Italy., Nichetti F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Agnelli L; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Lobefaro R; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Fucà G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Fotia G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Mariani L; Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Morelli D; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Ladisa V; Hospital Pharmacy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., De Santis MC; Department of Radiology and Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Lozza L; Department of Radiology and Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Trecate G; Department of Radiology and Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Belfiore A; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Brich S; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Bertolotti A; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Lorenzini D; Oncology and Hematology-Oncology Department, University of Milan, Via Festa del Perdono 7, 20122 Milano, Italy; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Ficchì A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Martinetti A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Sottotetti E; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Arata A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Corsetto P; Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy., Sorrentino L; Surgical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Rediti M; IFOM ETS, the AIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy., Salvadori G; IFOM ETS, the AIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy., Minucci S; Oncology and Hematology-Oncology Department, University of Milan, Via Festa del Perdono 7, 20122 Milano, Italy; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139 Milan, Italy., Foiani M; IFOM ETS, the AIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy; Oncology and Hematology-Oncology Department, University of Milan, Via Festa del Perdono 7, 20122 Milano, Italy., Apolone G; Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Pagani M; IFOM ETS, the AIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy; Department of Medical Biotechnology and Translational Medicine, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy., Pruneri G; Oncology and Hematology-Oncology Department, University of Milan, Via Festa del Perdono 7, 20122 Milano, Italy; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., de Braud F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy; Oncology and Hematology-Oncology Department, University of Milan, Via Festa del Perdono 7, 20122 Milano, Italy., Vernieri C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy; IFOM ETS, the AIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy. Electronic address: claudio.vernieri@istitutotumori.mi.it.

Publikováno v: Cell metabolism [Cell Metab] 2024 Dec 14. Date of Electronic Publication: 2024 Dec 14.

Broken discrete and continuous symmetries in two dimensional spiral antiferromagnets

Autor: Mezio, A., Sposetti, C. N., Manuel, L. O., Trumper, A. E.

We study the occurrence of symmetry breakings, at zero and finite temperatures, in the J_1-J_3 antiferromagnetic Heisenberg model on the square lattice using Schwinger boson mean field theory. For spin-1/2 the ground state breaks always the SU(2) sym

Externí odkaz: http://arxiv.org/abs/1310.4798

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.

Autor: Botticelli A; Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy., Caputo R; Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Pascale, Naples, Italy., Scagnoli S; Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy., Pisegna S; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy., De Laurentiis M; Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Pascale, Naples, Italy., Curigliano G; Department of Oncology and Hematology, University of Milan, Milan, Italy.; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Lambertini M; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.; Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Pantano F; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy., Palazzo A; Depatment of Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy., Paris I; Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Vernieri C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy., Tedesco B; Medical Oncology Unit, 'S. Carlo' Hospital, Italy., Giampaglia M; Medical Oncology Unit, 'S. Carlo' Hospital, Italy., Palleschi M; IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' IRST, Meldola, Italy., Ballatore Z; Clinical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti, Ancona, Italy., Alesini D; UOSD Centro Oncologico S. Spirito e Nuovo Regina Margherita, Ospedale Santo Spirito in Sassia, Rome, Italy., D'Auria G; Department of Medical Oncology, Sandro Pertini Hospital, RomeItaly., Fabbri A; Department of Oncology and Hematology, Medical Oncology and Breast Unit, Central Hospital of Belcolle, Viterbo, Italy., Rossi L; Multispeciality Department of Oncology, ASL Latina, 'Sapienza' University of Rome, Aprilia, Italy., Verrazzo A; Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Pascale, Naples, Italy., Scafetta R; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy., Marinelli D; Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy., Sposetti C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Barberi V; Sapienza Università di Roma - IRCCS Istituto Nazionale Tumori Regina Elena, RomeItaly., Strigari L; Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Marchetti P; Department of Oncology and Dermatological Oncology, Istituto Dermopatico dell'Immacolata IDI IRCCS, Rome, Italy., Santini D; Department of Medico-Surgical Sciences and Biotechnology, Polo Pontino, Sapienza University of Rome, Rome, Italy.; Medical Oncology A, AOU Policlinico Umberto I, Rome, Italy., Fabi A; Precision Medicine in Senology, Scientific Directorate - Department of Women and Child Health, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.

Publikováno v: The oncologist [Oncologist] 2024 Apr 04; Vol. 29 (4), pp. 303-310.

225P Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC): Retrospective multicentre analysis of post-progression treatments

Autor: Valenza, C., Trapani, D., Sposetti, C., Bielo, L. Boscolo, Marra, A., Giarratano, T., Cortesi, L., Moscetti, L., Pistelli, M., Berardi, R., Zambelli, A., Guarneri, V., Vernieri, C., Curigliano, G.

Publikováno v: In ESMO Open May 2023 8(1) Supplement 4

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.

Autor: Zattarin E; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Mariani L; Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Menichetti A; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy., Leporati R; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Provenzano L; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ligorio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy., Fucà G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lobefaro R; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lalli L; Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Vingiani A; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Nichetti F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Griguolo G; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology-DiSCOG, University of Padova, Padova, Italy., Sirico M; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Bernocchi O; Farmacia Ospedaliera ASST Cremona, Cremona, Lombardia, Italy., Marra A; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Corti C; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy., Zagami P; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy., Agostinetto E; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Institut Jules Bordet and l'Université Libre de Bruxelles, Bruxelles, Belgium., Jacobs F; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Di Mauro P; Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy., Presti D; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sposetti C; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Giorgi CA; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy., Guarneri V; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology-DiSCOG, University of Padova, Padova, Italy., Pedersini R; Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy., Losurdo A; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Generali D; Breast Cancer Unit & Translational Research Unit, ASST Cremona, Cremona, Italy.; Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy., Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy., Pruneri G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., de Braud F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Dieci MV; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology-DiSCOG, University of Padova, Padova, Italy., Vernieri C; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan 20133, Italy IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Dec 20; Vol. 15, pp. 17588359231204857. Date of Electronic Publication: 2023 Dec 20 (Print Publication: 2023).